First Tracks Biotherapeutics, Inc.
- TRAX ยท Nasdaq
- Pharmaceutical Preparations
- San Diego, CA
- CIK 0002091349
Updated from SEC filings through
Top things to know
Executives
-
Daniel Faga President and chief executive officer 8-K, November 3, 2026 -
Ajim Tamboli Chief Financial Officer Form 4, May 14, 2026 - Benjamin Stone Chief Business Officer Form 4, August 18, 2026
- Paul F. Lizzul Chief Medical Officer Form 4, August 18, 2026
What leadership is saying
“ANB033, a subcutaneously administered CD122 antagonist designed to inhibit signaling of both IL-15 and IL-2 on immune cells, demonstrated statistically significant protection against gluten-induced intestinal damage and symptoms and was well tolerated in the Phase 1b gluten-challenge cohort. These data support our plans to progress ANB033 into late-stage development in 2027 in celiac disease as a potential treatment to prevent both acute symptoms and intestinal damage from gl”
Earnings press release (8-K Ex. 99.1), filed November 3, 2026
First Tracks Biotherapeutics, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in San Diego, CA. It trades as TRAX on Nasdaq. Daniel Faga is President and chief executive officer.
Five-year financials
We have no annual financials for this company yet.
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| | President and chief executive officer | 8-K, November 3, 2026 |
| Chief Financial Officer | Chief Financial Officer | Form 4, May 14, 2026 |
| Benjamin Stone Chief Business Officer at First Tracks Biotherapeutics | Chief Business Officer | Form 4, August 18, 2026 |
| Paul F. Lizzul | Chief Medical Officer | Form 4, August 18, 2026 |
What First Tracks Biotherapeutics, Inc. does
First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator.com or follow us on LinkedIn .
Press release "About" paragraph, 10-K for the year ending October 15, 2026
Shares and governance
| Shares outstanding | 42.0 million (as of October 29, 2026) | 10-Q, November 3, 2026 |
|---|---|---|
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 3, 2026 |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| September 2, 2026 | J. Anthony Ware Director | Sale | 39,265 | $1.8M | Form 4, September 4, 2026 |
Recent 8-K events
- 8-K filed 2026-11-03
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-10-20
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-10-15
- Item 1.01 Entry into a material definitive agreement
- Item 3.02 Unregistered sales of equity securities
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-10-13
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-08-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-22
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-05-14
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-20
- Item 1.01 Entry into a material definitive agreement
- Item 2.01 Completion of acquisition or disposition of assets
- Item 3.02 Unregistered sales of equity securities
- Item 3.03 Material modification to rights of security holders
- Item 5.01 Changes in control of registrant
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 8.01 Other events
- 8-K filed 2026-04-03
- Item 7.01 Regulation FD disclosure
Frequently asked questions about First Tracks Biotherapeutics, Inc.
- What does First Tracks Biotherapeutics, Inc. do?
- In its own words, from Item 1 of its 10-K: "First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator.com or follow us on LinkedIn ."
- Who is the CEO of First Tracks Biotherapeutics, Inc.?
- Daniel Faga, President and chief executive officer, as named in a 8-K filed November 3, 2026.
- Who is the CFO of First Tracks Biotherapeutics, Inc.?
- Ajim Tamboli, Chief Financial Officer, as named in a 4 filed May 14, 2026.
- Where is First Tracks Biotherapeutics, Inc. headquartered?
- San Diego, CA.
- What is First Tracks Biotherapeutics, Inc.'s stock ticker?
- TRAX on Nasdaq.
- What industry is First Tracks Biotherapeutics, Inc. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is First Tracks Biotherapeutics, Inc.'s website?
- firsttracksbio.com. Investor relations: https://ir.firsttracksbio.com/news-events/news-releases.
- When does First Tracks Biotherapeutics, Inc. report earnings next?
- February 2, 2027. This is an estimate from past filing dates, not a confirmed date.
- Is First Tracks Biotherapeutics, Inc. a public company?
- Yes. First Tracks Biotherapeutics, Inc. files with the SEC under CIK 0002091349 and trades as TRAX.
- How many shares of First Tracks Biotherapeutics, Inc. are outstanding?
- 42.0 million shares as of October 29, 2026, from its 10-Q filed November 3, 2026.
- How many business segments does First Tracks Biotherapeutics, Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 3, 2026.
- Have First Tracks Biotherapeutics, Inc. insiders traded stock recently?
- Since September 2, 2026, officers and directors reported 1 open-market sale worth about $1.8M and 0 purchases on Forms 4 and 5. The most recent: J. Anthony Ware (Director) sold 39,265 shares on September 2, 2026.